BIOMAT Database Logo BIOMAT Database Logo

[Therapy of patients with head and neck neoplasms using cytotoxic T lymphocytes]. 1995

IshikawaT, and M Eura, and K Chikamatsu, and T Fukie, and K Murakami, and H Matsuoka, and K Nakano, and Y Sameshima, and K Masuyama, and T Inokawa

UI MeSH Term Description Entries
D007167 Immunotherapy Manipulation of the host's immune system in treatment of disease. It includes both active and passive immunization as well as immunosuppressive therapy to prevent graft rejection. Immunotherapies
D002294 Carcinoma, Squamous Cell A carcinoma derived from stratified SQUAMOUS EPITHELIAL CELLS. It may also occur in sites where glandular or columnar epithelium is normally present. (From Stedman, 25th ed) Carcinoma, Epidermoid,Carcinoma, Planocellular,Carcinoma, Squamous,Squamous Cell Carcinoma,Carcinomas, Epidermoid,Carcinomas, Planocellular,Carcinomas, Squamous,Carcinomas, Squamous Cell,Epidermoid Carcinoma,Epidermoid Carcinomas,Planocellular Carcinoma,Planocellular Carcinomas,Squamous Carcinoma,Squamous Carcinomas,Squamous Cell Carcinomas
D003001 Cloning, Molecular The insertion of recombinant DNA molecules from prokaryotic and/or eukaryotic sources into a replicating vehicle, such as a plasmid or virus vector, and the introduction of the resultant hybrid molecules into recipient cells without altering the viability of those cells. Molecular Cloning
D003131 Combined Modality Therapy The treatment of a disease or condition by several different means simultaneously or sequentially. Chemoimmunotherapy, RADIOIMMUNOTHERAPY, chemoradiotherapy, cryochemotherapy, and SALVAGE THERAPY are seen most frequently, but their combinations with each other and surgery are also used. Multimodal Treatment,Therapy, Combined Modality,Combined Modality Therapies,Modality Therapies, Combined,Modality Therapy, Combined,Multimodal Treatments,Therapies, Combined Modality,Treatment, Multimodal,Treatments, Multimodal
D006258 Head and Neck Neoplasms Soft tissue tumors or cancer arising from the mucosal surfaces of the LIP; oral cavity; PHARYNX; LARYNX; and cervical esophagus. Other sites included are the NOSE and PARANASAL SINUSES; SALIVARY GLANDS; THYROID GLAND and PARATHYROID GLANDS; and MELANOMA and non-melanoma skin cancers of the head and neck. (from Holland et al., Cancer Medicine, 4th ed, p1651) Cancer of Head and Neck,Head Cancer,Head Neoplasm,Head and Neck Cancer,Head and Neck Neoplasm,Neck Cancer,Neck Neoplasm,Neck Neoplasms,Neoplasms, Upper Aerodigestive Tract,UADT Neoplasm,Upper Aerodigestive Tract Neoplasm,Upper Aerodigestive Tract Neoplasms,Cancer of Head,Cancer of Neck,Cancer of the Head,Cancer of the Head and Neck,Cancer of the Neck,Head Neoplasms,Head, Neck Neoplasms,Neoplasms, Head,Neoplasms, Head and Neck,Neoplasms, Neck,UADT Neoplasms,Cancer, Head,Cancer, Neck,Cancers, Head,Cancers, Neck,Head Cancers,Neck Cancers,Neoplasm, Head,Neoplasm, Neck,Neoplasm, UADT,Neoplasms, UADT
D006680 HLA Antigens Antigens determined by leukocyte loci found on chromosome 6, the major histocompatibility loci in humans. They are polypeptides or glycoproteins found on most nucleated cells and platelets, determine tissue types for transplantation, and are associated with certain diseases. Human Leukocyte Antigen,Human Leukocyte Antigens,Leukocyte Antigens,HL-A Antigens,Antigen, Human Leukocyte,Antigens, HL-A,Antigens, HLA,Antigens, Human Leukocyte,Antigens, Leukocyte,HL A Antigens,Leukocyte Antigen, Human,Leukocyte Antigens, Human
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000951 Antigens, Neoplasm Proteins, glycoprotein, or lipoprotein moieties on surfaces of tumor cells that are usually identified by monoclonal antibodies. Many of these are of either embryonic or viral origin. Neoplasm Antigens,Tumor Antigen,Tumor Antigens,Antigen, Tumor,Antigens, Tumor
D013602 T-Lymphocytes, Cytotoxic Immunized T-lymphocytes which can directly destroy appropriate target cells. These cytotoxic lymphocytes may be generated in vitro in mixed lymphocyte cultures (MLC), in vivo during a graft-versus-host (GVH) reaction, or after immunization with an allograft, tumor cell or virally transformed or chemically modified target cell. The lytic phenomenon is sometimes referred to as cell-mediated lympholysis (CML). These CD8-positive cells are distinct from NATURAL KILLER CELLS and NATURAL KILLER T-CELLS. There are two effector phenotypes: TC1 and TC2. Cell-Mediated Lympholytic Cells,Cytotoxic T Cells,Cytotoxic T Lymphocyte,Cytotoxic T-Lymphocytes,TC1 Cell,TC1 Cells,TC2 Cell,TC2 Cells,Cell Mediated Lympholytic Cells,Cell, Cell-Mediated Lympholytic,Cell, TC1,Cell, TC2,Cell-Mediated Lympholytic Cell,Cytotoxic T Cell,Cytotoxic T Lymphocytes,Cytotoxic T-Lymphocyte,Lymphocyte, Cytotoxic T,Lympholytic Cell, Cell-Mediated,Lympholytic Cells, Cell-Mediated,T Cell, Cytotoxic,T Lymphocyte, Cytotoxic,T Lymphocytes, Cytotoxic,T-Lymphocyte, Cytotoxic

Related Publications

IshikawaT, and M Eura, and K Chikamatsu, and T Fukie, and K Murakami, and H Matsuoka, and K Nakano, and Y Sameshima, and K Masuyama, and T Inokawa
[Nutrition therapy in patients with head and neck neoplasms].
April 1990, Giornale di clinica medica,
IshikawaT, and M Eura, and K Chikamatsu, and T Fukie, and K Murakami, and H Matsuoka, and K Nakano, and Y Sameshima, and K Masuyama, and T Inokawa
[Molecular targeting therapy for patients with head and neck neoplasms].
July 2012, Nihon Jibiinkoka Gakkai kaiho,
IshikawaT, and M Eura, and K Chikamatsu, and T Fukie, and K Murakami, and H Matsuoka, and K Nakano, and Y Sameshima, and K Masuyama, and T Inokawa
[Enteral feeding therapy in patients with head and neck neoplasms].
November 1997, HNO,
IshikawaT, and M Eura, and K Chikamatsu, and T Fukie, and K Murakami, and H Matsuoka, and K Nakano, and Y Sameshima, and K Masuyama, and T Inokawa
Therapy of head and neck neoplasms.
September 1977, Clinical oncology,
IshikawaT, and M Eura, and K Chikamatsu, and T Fukie, and K Murakami, and H Matsuoka, and K Nakano, and Y Sameshima, and K Masuyama, and T Inokawa
Immune Checkpoint Inhibitors Regulate K+ Channel Activity in Cytotoxic T Lymphocytes of Head and Neck Cancer Patients.
January 2021, Frontiers in pharmacology,
IshikawaT, and M Eura, and K Chikamatsu, and T Fukie, and K Murakami, and H Matsuoka, and K Nakano, and Y Sameshima, and K Masuyama, and T Inokawa
T-lymphocytes phenotype and functions in patients with head and neck cancer.
May 1985, The Laryngoscope,
IshikawaT, and M Eura, and K Chikamatsu, and T Fukie, and K Murakami, and H Matsuoka, and K Nakano, and Y Sameshima, and K Masuyama, and T Inokawa
[Gene therapy of head and neck neoplasms].
February 1998, Lin chuang er bi yan hou ke za zhi = Journal of clinical otorhinolaryngology,
IshikawaT, and M Eura, and K Chikamatsu, and T Fukie, and K Murakami, and H Matsuoka, and K Nakano, and Y Sameshima, and K Masuyama, and T Inokawa
[Gene therapy of head and neck neoplasms].
June 2007, Zhonghua er bi yan hou tou jing wai ke za zhi = Chinese journal of otorhinolaryngology head and neck surgery,
IshikawaT, and M Eura, and K Chikamatsu, and T Fukie, and K Murakami, and H Matsuoka, and K Nakano, and Y Sameshima, and K Masuyama, and T Inokawa
Photodynamic therapy for head and neck neoplasms.
December 1991, Otolaryngologic clinics of North America,
IshikawaT, and M Eura, and K Chikamatsu, and T Fukie, and K Murakami, and H Matsuoka, and K Nakano, and Y Sameshima, and K Masuyama, and T Inokawa
[Cryo-ultrasonic therapy of head and neck neoplasms].
January 1978, Vestnik Akademii meditsinskikh nauk SSSR,
Copied contents to your clipboard!